EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia

Marta Santaliestra iD, Marta Garrote, María Concepción Fernández-Rodríguez, Patricia Vélez, Alicia Senín, Eduardo Arellano-Rodrigo, Neus Garcia-Gisbert, Raquel Longarón, Manuel Pérez-Encinas, Gonzalo Caballero-Navarro, Maria Soledad Noya-Pereira, Beatriz Cuevas und 17 weitere

HemaSphere · 2026-03 · 10 (3)

DOI: 10.1002/hem3.70325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 23.03.2026. Verfasst von Marta Santaliestra und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitari Mútua Terrassa Terrassa Spain. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Response to cytoreductive therapy according to CALR mutation type, CALR variant allele frequency (VAF), and additional mutations has not been previously studied in essential thrombocythemia (ET). The impact of the molecular profile on treatment response and the main clinical outcomes was analyzed in 557 CALR ET patients ( CALR Type 1, n = 339, median VAF 36%; and CALR Type 2, n = 218, median VAF 35%). NGS data on additional mutations were available for 257 patients. CALR Type 2 showed a significantly higher rate of complete hematological response (CHR) to first‐line cytoreduction. However, in the multivariate analysis, the effect of CALR mutation type in response rates was no longer significant once CALR VAF was considered, whereas high VAF remained independently associated with a lower likelihood of achieving CHR (hazard ratio [HR] = 0.482, 95% confidence interval (CI): 0.297–0.781; P = 0.003). Moreover, high VAF was also associated with an increased risk of arterial thrombosis (HR = 4.135, 95% CI: 1.093–15.645; P = 0.037), and progression to MF (HR = 2.631, 95% CI: 1.004–6.890; P = 0.049). Although allele burden affects overall survival (OS) in the entire population, its impact was surpassed by the presence of high molecular risk (HMR) mutations (HR = 2.114, 95% CI: 1.070–4.176; P = 0.031). Furthermore, the HMR profile was also associated with a higher risk of progression to acute leukemia, while it did not influence the probability of CHR or progression to MF. In conclusion, CALR VAF and HMR profile appear to be more important than CALR mutation type regarding treatment response and major clinical outcomes in ET.

Autor:innen und Institutionen

  • Hospital Universitari Mútua Terrassa Terrassa Spain.
  • Facultat de Medicina i Ciències de la Salut Universitat de Barcelona Barcelona Spain.
  • Hospital Clínic de Barcelona, IDIBAPS Barcelona Spain.
  • Hospital del Mar Barcelona Spain.
  • Institut Català d'Oncologia - Hospital Duran i Reynals Hospitalet del Llobregat Spain.
  • Complexo Hospitalario Universitario de Santiago Universidad de Santiago de Compostela Santiago de Compostela Spain.

ORCID-Profile: Marta Santaliestra, Ruth Stuckey

Zitieren

APA

Santaliestra, M., Garrote, M., Fernández-Rodríguez, M. C., Vélez, P., Senín, A., Arellano-Rodrigo, E., Garcia-Gisbert, N., Longarón, R., Pérez-Encinas, M., Caballero-Navarro, G., Noya-Pereira, M. S., Cuevas, B., Gómez-Casares, M. T., Stuckey, R., Carreño-Tarragona, G., Ferrer-Marin, F., Cortés, M. A., Magro, E., Mata, I., …, & Alvarez-Larran, A. (2026). Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia. HemaSphere, 10(3). https://doi.org/10.1002/hem3.70325

Vancouver

Santaliestra M, Garrote M, Fernández-Rodríguez MC, Vélez P, Senín A, Arellano-Rodrigo E, et al. Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia. HemaSphere. 2026;10(3). doi:10.1002/hem3.70325

BibTeX
@article{Santaliestra2026,
  author = {Santaliestra, Marta and Garrote, Marta and Fernández-Rodríguez, María Concepción and Vélez, Patricia and Senín, Alicia and Arellano-Rodrigo, Eduardo and Garcia-Gisbert, Neus and Longarón, Raquel and Pérez-Encinas, Manuel and Caballero-Navarro, Gonzalo and Noya-Pereira, Maria Soledad and Cuevas, Beatriz and Gómez-Casares, María Teresa and Stuckey, Ruth and Carreño-Tarragona, Gonzalo and Ferrer-Marin, Francisca and Cortés, Miguel Angel and Magro, Elena and Mata, Isabel and Angona, Anna and Pérez, Raúl and Fox, María Laura and Pastor-Galán, Irene and Sastre, Paula and Triguero, Ana and García-Gutierrez, Valentín and Hernández-Boluda, Juan Carlos and Bellosillo, Beatriz and Alvarez-Larran, Alberto},
  title = {Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1002/hem3.70325}
}
Kostenlos starten →